Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
PNU-EDA-Gly5
0 ImagesCat. No.: HY-145078CAS No.: 1957223-28-7PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5.
-
L2-FK866
0 ImagesCat. No.: HY-181911L2-FK866 is an ADC payload-linker conjugate (Drug-linker conjugate for ADC). L2-FK866 contains the ADC linker (Val-Cit-p-aminobenzyl) and the NAMPT inhibitor FK866 (HY-50876). L2-FK866 can be conjugated with Dinutuximab (HY-P9933) to form an ADC. L2-FK866 is applicable to neuroblastoma research.
-
APL-1092
0 ImagesCat. No.: HY-169324CAS No.: 2921735-91-1Synonyms: Mal-Exo-EEVC-ExatecanAPL-1092 is an EEVC linker-payload conjugate composed of exatecan, a stabilizer that prevents premature payload release, and a cleavage substrate for cathepsin B. APL-1092 resists premature payload release mediated by human neutrophil elastase and carboxylesterase, maintains payload stability in mouse plasma, and retains cathepsin B-mediated cleavage activity in target cells. APL-1092 exhibits dose-dependent tumor growth inhibition in xenograft mice. APL-1092 can be used in gastric cancer-related research.
-
Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan
0 ImagesCat. No.: HY-178145CAS No.: 3067680-81-0Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan (compound 12) is a Drug-Linker Conjugate for ADC. Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan contains the ADC linker (Mc-Lys(PEG12)-Cap-Ala-Ala-PABC) (HY-178146) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan can be used for the development of ADC targeting HER2-positive breast cancer.
-
SM00465
0 ImagesCat. No.: HY-164133CAS No.: 2983179-22-0SM00465 (Compound 207) is a Cbl-b inhibitor-linker conjugate composed of INT4 (HY-179262) and Linker (HY-179263). SM00465 can be used for ADC synthesis. SM00465 is applicable to the research of immune-related diseases.
-
Val-Cit-PAB-DEA-Duo-DM
0 ImagesCat. No.: HY-164303CAS No.: 1698870-53-9Val-Cit-PAB-DEA-Duo-DM is a drug-linker conjugate, which consists of the linker Val-Cit-PAB, the spacer DEA and the ADC toxin Duocarmycin DM (Duo-DM) (HY-130978). Val-Cit-PAB-DEA-Duo-DM can be used for the synthesis of ADC molecule.
-
DBA-DM4
0 ImagesCat. No.: HY-128960CAS No.: 905449-84-5DBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM1 and a linker SPDP to make antibody agent conjugate (ADC).
-
OSu-Val-Cit-PAB-Exa
0 ImagesCat. No.: HY-186185CAS No.: 3091519-75-1OSu-Val-Cit-PAB-Exa (compound D) is a cleavable linker-payload conjugate (usable for ADC synthesis). OSu-Val-Cit-PAB-Exa bears an N-terminal N-hydroxysuccinimide (OSu) ester group, and comprises Val-Cit, p-aminobenzyl alcohol (PAB) and Exatecan (HY-13631). OSu-Val-Cit-PAB-Exa serves as a payload-linker intermediate for polypeptide conjugation.
-
ATAC21
0 ImagesCat. No.: HY-148459CAS No.: 2101204-23-1ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate.
-
Mal-PEG8-Phe-Lys-PAB-Exatecan
0 ImagesCat. No.: HY-148380CAS No.: 2679821-44-2
-
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT
0 ImagesCat. No.: HY-164163CAS No.: 2378428-24-9MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT (example 4-3) is an ADC drug-linker conjugate composed of an payload 7-MAD-MDCPT (HY-132162) and a linker MP-PEG8-Val-Lys-Gly (HY-179261), used for synthesizing ADC.
-
N-(Hexanoyloxy)succinimide-MMAE
0 ImagesCat. No.: HY-179327CAS No.: 1404073-15-9N-(Hexanoyloxy)succinimide-MMAE is a conjugate of the ADC drug toxin molecule and the linker, containing a degradable PEG linker and the toxin molecule MMAE (HY-15162).
-
Rha-PEG3-SMCC
0 ImagesCat. No.: HY-142740CAS No.: 2794904-62-2Rha-PEG3-SMCC (compound 13) is a agent-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.
-
DBCO-HS-PEG2-VA-PABC-SG3199
0 ImagesCat. No.: HY-176807CAS No.: 3052634-58-6DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate for ADC. DBCO-HS-PEG2-VA-PABC-SG3199 consists of a SG3199 (HY-101161) based DNA small channel crosslinker and cleavable linker. DBCO-HS-PEG2-VA-PABC-SG3199 can be used for synthesis of ADCs.
-
Fmoc-Val-Lys(Boc)-PAB-Exatecan
0 ImagesCat. No.: HY-178289CAS No.: 2901788-26-7Fmoc-Val-Lys(Boc)-PAB-Exatecan (Compound 39-7) is a Drug-Linker Conjugates for ADC. Fmoc-Val-Lys(Boc)-PAB-Exatecan consists of the ADC Cytotoxin Exatecan (HY-13631) and a linker PAB-Val-Lys-Boc (HY-138651). Fmoc-Val-Lys(Boc)-PAB-Exatecan can be used for synthesis of ADCs.
-
Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE
0 ImagesCat. No.: HY-148227CAS No.: 2226490-67-9Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE (HY-15162) and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid (HY-171663) .
-
STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal
0 ImagesCat. No.: HY-179659CAS No.: 2803608-01-5STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal (compound gluc-cSTING linker-payload) is a drug-linker conjugate for ADC. STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal can be used for ADC synthesis.
